How Digitalization optimizes Clinical Trials
Published: 10.14.2021
Clinical trials are time-consuming and costly. Yet digital innovations offer promising opportunities for the future.
The approval of new drugs is not only time-intensive but also expensive. After a drug is developed, it is tested in various phases of clinical trials before it receives final approval. These are lengthy processes that often take many years—years that can be critical for patients waiting for a potential treatment.
Digitalization and new technologies are not only optimizing the development and execution of clinical trials but also creating new opportunities for patients. Modern digital tools can improve data quality, accelerate research, and ultimately reduce costs.
More Efficiency Through Digital Clinical Trials
In the future, clinical trials will increasingly be conducted virtually with the help of high-quality datasets. The goal is not to replace traditional trials entirely but to enhance them with digital components.
Electronic patient diaries, remote monitoring, and cloud-based systems enable more precise data collection—thereby improving data quality. The seamless integration of these digital technologies into existing processes not only saves time but also reduces the likelihood of human error.
Digital clinical trials also make research processes more transparent and traceable, increasing the acceptance of results within the scientific and regulatory communities.
White Paper
Big Data Solutions in Clinical Trials
Simulating a clinical trial allows the effects of medications or therapies to be tested virtually. This virtual execution can reveal early administrative errors or potential side effects, which can then be addressed proactively. This helps optimize processes before therapies are tested on humans during actual clinical trials.
Big Data introduces a whole new level of analysis: large, complex datasets are evaluated using modern technologies like machine learning to identify patterns that would remain hidden with traditional methods. These solutions increase the efficiency and robustness of clinical trials—while simultaneously reducing costs, as inefficient trial arms can be identified and discontinued earlier.
Virtual Patients in Clinical Trials
How can a study be conducted when there are not enough patients? One possible solution is the development of a virtual patient. By digitally recreating the human anatomy, additional participants are generated. These simulations are used to test therapies from early development to long-term monitoring. This approach can make future clinical trials faster and more efficient.
This technology can also help realistically represent rare diseases and enable targeted research. Virtual patient models not only increase efficiency but also improve data quality, as they can be tested under controlled conditions. In the long term, such solutions could bridge the gap between preclinical research and actual patient care.
Wearables for Data Collection
Various wearables offer the opportunity to collect and analyze data in clinical trials more efficiently and quickly. Small devices like smartwatches or fitness trackers measure vital signs directly on the patient’s body and transmit them via the cloud to the study centers. This allows for significantly faster and more comprehensive data collection.
Thanks to these digital technologies, data can be collected and monitored in real time—an enormous improvement over conventional documentation. This not only enhances data quality but also reduces costs due to lower personnel and time requirements.
Patient comfort also improves: external measurement devices and manual data entry are often no longer necessary. In addition, patients become more aware of their own vital signs and can respond more quickly to changes in their health—a benefit for both research and the quality of care.
More Flexibility in Clinical Trials Through Telemedicine
Telemedicine is another digital approach that has gained popularity, especially since the COVID-19 pandemic. Instead of meeting in person, doctors now conduct clinical study consultations via video conferencing platforms.
This benefits not only doctors and patients but also the clinical trials themselves, as they can recruit participants regardless of location. Moreover, telemedicine allows for more continuous patient support—another factor that can enhance data quality.
Digital channels also offer new ways to engage and retain patients by simplifying the trial experience and lowering participation barriers. This indirectly reduces the cost per participant and increases the likelihood of trial success.
Artificial Intelligence in Clinical Trials
Artificial intelligence (AI) has many applications in clinical trials. For example, AI is used to analyze collected data more quickly, flexibly, and reliably through data management systems. Traditionally, data is analyzed at the end of a trial. AI, however, enables analysis during the trial itself, helping to detect and correct manual errors earlier.
AI can also predict potential risks, side effects, or treatment outcomes. By combining modern AI algorithms with digital technologies, a new dimension of research is emerging: faster, data-driven, and more targeted. This intelligent analysis leads to faster decision-making during trial execution—a key factor in reducing costs and improving data quality.
Challenges on the Path Toward Digital Clinical Trials
Innovation often comes with challenges—especially in a sensitive sector like healthcare. New digital approaches must be thoroughly evaluated before implementation. Key challenges on the road to digitalization include:
Large, high-quality datasets required for AI-supported clinical trial simulations are currently in short supply. Data quality is crucial to the success of digital trials, yet uniform data collection standards are often lacking. Technological solutions are urgently needed to systematically prepare and make data usable.
The centralization and standardization of data remain difficult for the industry. Only when collected data is available in a consistent format can it be used for further analysis and evaluation. However, study data is often gathered via a wide variety of technical devices, making standardization more complex.
In addition, the number of validation studies is currently very low. These studies assess whether a drug or therapy improves patient health under the specific conditions of a clinical trial. Until Big Data results are sufficiently compared with validation studies, they should be analyzed and used with caution.
Further research is needed to establish robust methodological standards for digital trials—an investment that will pay off in the medium to long term through lower costs and better outcomes.